Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1714027

registered interest
date	26/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Sipavibart
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the oral contribution by the Parliamentary Under Secretary of State at the Department of Health and Social Care during the debate on Covid-19: Response and Excess Deaths on Thursday 18 April 2024, Official Report, column 537, whether she has had recent discussions with (a) NICE and (b) the MHRA on their progress on reaching a decision on whether to recommend the use of Evusheld 2 to prevent covid-19.
tabling member constituency	Christchurch
tabling member printed	Sir Christopher Chope
uin	23829
answer	answer is ministerial correction date of answer 01/05/2024 answer text <p>The Department meets with the National Institute of Health and Care Excellence (NICE) regularly to discuss a range of issues, including access to medicines. The NICE has formally started its appraisal of AZD-3152, also known as sipavibart and referred to as Evusheld 2, ahead of the Medicines and Healthcare products Regulatory Agency’s (MHRA) decision on whether it should be given a United Kingdom marketing authorisation, and expects to invite stakeholder submissions in April 2024. Timelines for both the NICE’s guidance and licensing depend on data from the SUPERNOVA trial being available. AstraZeneca intends to submit clinical data to the NICE and the MHRA at the same time, with the aim that both organisations are able to reach decisions as close together as possible. If AZD-3152 is recommended as clinically and cost effective by the NICE, the National Health Service in England will be under a statutory requirement to fund AZD-3152 for eligible patients, in line with the NICE’s recommendations.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 01/05/2024 08:57:40 answering member 4044 label Biography information for Andrew Stephenson
tabling member	242 label Biography information for Sir Christopher Chope

1714094

registered interest
date	26/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Heart Diseases: Surgery
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to help increase the availability of heart valve surgery for (a) women and (b) ethnic minorities.
tabling member constituency	Sheffield, Brightside and Hillsborough
tabling member printed	Gill Furniss
uin	23907
answer	answer is ministerial correction date of answer 01/05/2024 answer text <p>NHS England continues to work with its partners in raising awareness of aortic stenosis, with a particular focus on women. NHS England is also working to increase access to cardiac surgery. The breathlessness pathway, launched in April 2023, encourages general practitioners to examine all patients for the signs of valvular heart disease. Heart valve disease is a focus for cardiac networks, with pathways in in place to improve early detection of valve disease in the community.</p><p>In November 2023, a dedicated Heart Valve Disease (HVD) Expert Advisory Group was convened to provide NHS England’s Cardiac Transformation Programme with leadership, advice, quality assurance, expert review, and endorsement of the projects and deliverables that comprise the HVD workstream, with a focus on improving the speed and equity of access to high quality treatment for heart valve patients.</p><p>To improve the early detection and diagnosis of heart valve disease across England, including aortic stenosis, £2.3 billion has been committed to open 160 community diagnostic centres by March 2025. This will increase the volume of diagnostic activity and further reduce patient waiting times. The centres have delivered over 5 million additional tests since July 2021, including those that detect cardiovascular disease.</p><p>In addition, the National Health Service is investing in cardiac networks to support whole pathway improvements. These networks have been developed to take an evidenced based, clinically led, whole pathway approach to improvement, from prevention, diagnosis, treatment, and through to end-of-life care.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 23908 question first answered 01/05/2024 08:52:14 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4571 label Biography information for Gill Furniss

1714095

registered interest
date	26/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Heart Diseases: Women
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to help increase awareness of the symptoms of heart valve disease in women.
tabling member constituency	Sheffield, Brightside and Hillsborough
tabling member printed	Gill Furniss
uin	23908
answer	answer is ministerial correction date of answer 01/05/2024 answer text <p>NHS England continues to work with its partners in raising awareness of aortic stenosis, with a particular focus on women. NHS England is also working to increase access to cardiac surgery. The breathlessness pathway, launched in April 2023, encourages general practitioners to examine all patients for the signs of valvular heart disease. Heart valve disease is a focus for cardiac networks, with pathways in in place to improve early detection of valve disease in the community.</p><p>In November 2023, a dedicated Heart Valve Disease (HVD) Expert Advisory Group was convened to provide NHS England’s Cardiac Transformation Programme with leadership, advice, quality assurance, expert review, and endorsement of the projects and deliverables that comprise the HVD workstream, with a focus on improving the speed and equity of access to high quality treatment for heart valve patients.</p><p>To improve the early detection and diagnosis of heart valve disease across England, including aortic stenosis, £2.3 billion has been committed to open 160 community diagnostic centres by March 2025. This will increase the volume of diagnostic activity and further reduce patient waiting times. The centres have delivered over 5 million additional tests since July 2021, including those that detect cardiovascular disease.</p><p>In addition, the National Health Service is investing in cardiac networks to support whole pathway improvements. These networks have been developed to take an evidenced based, clinically led, whole pathway approach to improvement, from prevention, diagnosis, treatment, and through to end-of-life care.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 23907 question first answered 01/05/2024 08:52:14 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4571 label Biography information for Gill Furniss

1713829

registered interest
date	25/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	General Practitioners: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what the cost to NHS England has been of reimbursing GP practices for providing services to (a) non-UK and (b) non-registered UK citizens in each of the last three years for which information is available.
tabling member constituency	Christchurch
tabling member printed	Sir Christopher Chope
uin	23670
answer	answer is ministerial correction date of answer 30/04/2024 answer text <p>General practices (GPs) are paid for providing essential services to all their patients via global sum payments, which are weighted to take patient needs into account. Therefore, there are no dedicated GP payments for providing services to non-United Kingdom or non-registered UK citizens, and the Department does not hold data on GP patient lists by nationality.</p> answering member constituency South Northamptonshire answering member printed Andrea Leadsom question first answered 30/04/2024 21:20:59 answering member 4117 label Biography information for Andrea Leadsom previous answer version 31584 answering member constituency South Northamptonshire answering member printed Andrea Leadsom answering member 4117 label Biography information for Andrea Leadsom
tabling member	242 label Biography information for Sir Christopher Chope

1713919

registered interest
date	25/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Alcoholic Drinks: Misuse
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if she will meet charities representing people affected by alcohol harm to inform her Department’s work on health prevention.
tabling member constituency	Stockport
tabling member printed	Navendu Mishra
uin	23807
answer	answer is ministerial correction date of answer 30/04/2024 answer text <p>The Department meets regularly with alcohol charity representatives, at a ministerial and official level, and is content to continue to do so, to support and inform our work in tackling alcohol related health harms.</p> answering member constituency South Northamptonshire answering member printed Andrea Leadsom question first answered 30/04/2024 21:24:32 answering member 4117 label Biography information for Andrea Leadsom previous answer version 31574 answering member constituency South Northamptonshire answering member printed Andrea Leadsom answering member 4117 label Biography information for Andrea Leadsom
tabling member	4811 label Biography information for Navendu Mishra

1713920

registered interest
date	25/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Alcoholic Drinks: Misuse
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether her Department has made a recent assessment of the potential merits of developing a cross-departmental strategy to tackle alcohol harm.
tabling member constituency	Stockport
tabling member printed	Navendu Mishra
uin	23808
answer	answer is ministerial correction date of answer 30/04/2024 answer text <p>The Government takes a wide-ranging approach to addressing alcohol-related harms, including through taking forward the commitments set out in Advancing our health: prevention in the 2020s, to increase the availability of no- and low-alcohol alternatives, establish alcohol care teams in the 25% of acute hospitals in England with the greatest need as part of the NHS Long Term Plan, and improve the alcohol and drug treatment system through the 10-year Drug Strategy.</p> answering member constituency South Northamptonshire answering member printed Andrea Leadsom question first answered 30/04/2024 21:25:45 answering member 4117 label Biography information for Andrea Leadsom previous answer version 31573 answering member constituency South Northamptonshire answering member printed Andrea Leadsom answering member 4117 label Biography information for Andrea Leadsom
tabling member	4811 label Biography information for Navendu Mishra

1713939

registered interest
date	25/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Electronic Cigarettes: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to educate people about the use of synthetic drugs in vapes.
tabling member constituency	York Central
tabling member printed	Rachael Maskell
uin	23762
answer	answer is ministerial correction date of answer 30/04/2024 answer text <p>The health advice is clear, if you don’t smoke, don’t vape, and children should never vape. Vaping can play a role in helping adult smokers to quit, but the number of children using vapes has tripled in the past three years, and a staggering 20.5% of children had tried vaping in March to April 2023</p><p>Drugs education is a mandatory component of the Relationships and Sex Education and Health Education curriculum taught in schools. The Office for Health Improvement and Disparities has commissioned the PSHE Association to publish teaching resources for schools on drug and alcohol use, and vaping. These resources are in the process of being updated, and there will be increased emphasis on the risks of synthetic drugs, including vapes.</p><p>Information on the dangers of using THC vapes is available on FRANK, the Government’s drug information and advisory website, which signposts users to support services and provides an around the clock and free-to-use confidential helpline, text and email message services, and an online chat.</p><p>Where there are incidents of synthetic cannabinoids in THC vapes, it is for the local authority public health team and the police force to take appropriate actions to warn and protect their at-risk populations, supported by regional teams.</p> answering member constituency South Northamptonshire answering member printed Andrea Leadsom question first answered 30/04/2024 21:23:21 answering member 4117 label Biography information for Andrea Leadsom previous answer version 31576 answering member constituency South Northamptonshire answering member printed Andrea Leadsom answering member 4117 label Biography information for Andrea Leadsom
tabling member	4471 label Biography information for Rachael Maskell

1713963

registered interest
date	25/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Opioids: Health Hazards
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps her Department has taken to help prepare for potential increases in levels of synthetic opioid-related harms.
tabling member constituency	Easington
tabling member printed	Grahame Morris
uin	23725
answer	answer is ministerial correction date of answer 30/04/2024 answer text <p>We are highly alert to the emerging threat from the arrival of potent synthetic opioids in the United Kingdom. The Department is an active member of the cross-Government synthetic opioids taskforce, which was established in the Summer of 2023, to develop mitigations to the synthetic opioids threat.</p><p>In July 2023, the Office for Health Improvement and Disparities issued a National Patient Safety Alert, which promoted awareness and provided clear instructions for staff in health settings across the country, to ensure they are prepared for anyone that may present with an overdose caused by synthetic opioids.</p><p>We are developing an early warning system to improve drug surveillance on synthetic opioids, and are also expanding access to naloxone, a lifesaving medicine that reverses the effects of an opioid overdose, so that more professionals and services can give out take-home supplies.</p><p>We are engaging on this issue internationally via the United Nations Commission on Narcotic Drugs, and are playing an active role in the United States-convened Global Coalition to Address Synthetic Drug Threats.</p> answering member constituency South Northamptonshire answering member printed Andrea Leadsom question first answered 30/04/2024 21:22:11 answering member 4117 label Biography information for Andrea Leadsom previous answer version 31579 answering member constituency South Northamptonshire answering member printed Andrea Leadsom answering member 4117 label Biography information for Andrea Leadsom
tabling member	3973 label Biography information for Grahame Morris